Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 362

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 362
---
 webinars, educational content and referrals, with the objective of generating awareness over the importance of clinical genetic tests for the health management of patients and their families. Business Development Overview We are focused on making comprehensive, high -qualitygenetic information more accessible and instrumental to the healthcare ecosystem and directly to the general population, to revolutionize health management. As we develop our products and grow, we expect to expand and evolve in the near future in the stages described below. Strategic partnerships and consortium development We are committed to driving transformational change in the healthcare industry by leveraging strategic partnerships and building a robust consortium of market participants. Our decade -longjourney of scientific and clinical innovation has laid the foundation for this next phase of growth. We are focused on creating a collaborative ecosystem that maximizes our competitive advantages while ensuring sustainable and scalable growth. The key elements of our approach include: • Hybrid laboratory infrastructure: we plan to employ a hybrid model for the wet lab processing requirements of the consortium, using both our own facilities and certified third -partylaboratories from its participants. For example, we plan to lease a facility in a mature market such as Mexico, and utilize the infrastructure of the laboratories within our consortium to process, if and when their respective market develops. This approach allows us to leverage our operating know -how, such as sample processing and sequencing for bioinformatic data creation, while enhancing capital efficiency, reducing risk, and providing accelerated market access; • Off -site bioinformatics support: to address the scarcity and cost of local expertise, our bioinformatics and data science teams provide cloud -basedanalyses that support local testing efforts. This ensures that our partners receive tailored, localized and precise results, further enhancing our value proposition in the region; • Local laboratory partnerships: many of our services are offered through local laboratory operators who have established distribution networks. These relationships are crucial, as they enable us to reach a broader market while integrating our services with complementary services such as auxiliary blood and other tests that we do not offer, recommended by the physicians involved. This integration makes our offering more appealing to our partners and their customers; • Healthcare providers: physicians play a critical role in the adoption and growth of clinical genomic healthcare. We will support market development initiatives for the participants in the consortium, conducting training programs and events with key opinion leaders to close the gap between technology adoption and the market; • Healthcare professional networks: our prevention solutions will be distinguished by the personalized support provided by the consultations with nutrigenetic specialists. In the medium to long term, we plan to enhance